Skip to content
Peptigraph home

Amycretin Phase 2 trial (NCT06542874)

Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
448
actual
Start
7 Aug 2024 (actual)
Primary completion
1 Oct 2025 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT06542874 study arms
ArmTypeInterventionsDescription
Placebo subcutaneousPlacebo comparatorDrug: Placebo (NNC0487-0111 subcutanous)Placebo for subcutaneous treatment
NNC0487-0111 subcutaneous dose 1ExperimentalDrug: NNC0487-0111 subcutanousNNC0487-0111 subcutaneous dose 1 treatment
NNC0487-0111 subcutaneous dose 2ExperimentalDrug: NNC0487-0111 subcutanousNNC0487-0111 subcutaneous dose 2 treatment
NNC0487-0111 subcutaneous dose 3ExperimentalDrug: NNC0487-0111 subcutanousNNC0487-0111 subcutaneous dose 3 treatment
NNC0487-0111 subcutaneous dose 4ExperimentalDrug: NNC0487-0111 subcutanousNNC0487-0111 subcutaneous dose 4 treatment
NNC0487-0111 subcutaneous dose 5ExperimentalDrug: NNC0487-0111 subcutanousNNC0487-0111 subcutaneous dose 5 treatment
NNC0487-0111 subcutaneous dose 6ExperimentalDrug: NNC0487-0111 subcutanousNNC0487-0111 subcutaneous dose 6 treatment
Placebo oralPlacebo comparatorDrug: Placebo (NNC0487-0111 oral)Placebo for oral treatment
NNC0487-0111 oral dose 1ExperimentalDrug: NNC0487-0111 oralNNC0487-0111 oral dose 1 treatment
NNC0487-0111 oral dose 2ExperimentalDrug: NNC0487-0111 oralNNC0487-0111 oral dose 2 treatment
NNC0487-0111 oral dose 3ExperimentalDrug: NNC0487-0111 oralNNC0487-0111 oral dose 3 treatment
Endpoints

Primary endpoint

NCT06542874 primary outcomes
MeasureTime frame
Change in HbA1cFrom baseline (week 0) to end of treatment (week 36)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06542874 secondary outcomes
MeasureTime frame
Relative change in body weightFrom baseline (week 0) to end of treatment (week 36)
Change in body weightFrom baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)From baseline (week 0) to end of treatment (week 36)
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)From baseline (week 0) to end of treatment (week 36)
Change in body mass index (BMI)From baseline (week 0) to end of treatment (week 36)
Change in waist circumferenceFrom baseline (week 0) to end of treatment (week 36)
Change in systolic blood pressure (SBP)From baseline (week 0) to end of treatment (week 36)
Change in average 24-hour systolic blood pressure (SBP)From baseline (week 0) to end of treatment (week 36)
Change in high sensitivity C-Reactive Protein (hsCRP)From baseline (week 0) to end of treatment (week 36)
Change in total cholesterolFrom baseline (week 0) to end of treatment (week 36)
Change in high-density lipoprotein (HDL) cholesterolFrom baseline (week 0) to end of treatment (week 36)
Change in low-density lipoprotein (LDL) cholesterolFrom baseline (week 0) to end of treatment (week 36)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding StudyClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.